AVE3085 protects coronary endothelium from the impairment of asymmetric dimethylarginine by activation and recoupling of enos

Cardiovascular Drugs and Therapy

Volumn 26, Issue 5, 2012, Pages 383-392

  Xue, Hong Mei ^a,b   Yu, Cheuk Man ^a   Underwood, Malcolm John ^a   Jun Huang, Hao ^a   Yang, Qin ^a,c  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b HEBEI MEDICAL UNIVERSITY   (China)

^c NANKAI UNIVERSITY   (China)

Author keywords

Cardiovascular diseases; Endothelium; Nitric oxide; Nitric oxide synthase; Oxidative stress

Indexed keywords

3 NITROTYROSINE; AVE 3085; BRADYKININ; CORONARY VASODILATING AGENT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; N(G),N(G) DIMETHYLARGININE; NITROPRUSSIDE SODIUM; OXYGEN; PEROXYNITRITE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CHEMOLUMINESCENCE; CONTROLLED STUDY; CORONARY ARTERY; ENDOTHELIAL DYSFUNCTION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SWINE; VASCULAR ENDOTHELIUM; VASODILATATION; WESTERN BLOTTING;

ANIMALS; ARGININE; BENZODIOXOLES; CARDIOTONIC AGENTS; CORONARY VESSELS; ENDOTHELIUM, VASCULAR; INDANS; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; OXYGEN; SUPEROXIDES; SWINE; VASODILATION;

EID: 84867990157     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-012-6404-2     Document Type: Article

References (48)

1. Clarke S. Protein methylation. Curr Opin Cell Biol. 1993;5:977-83. (Pubitemid 23340504)
2. McBride AE, Silver PA. State of the Arg: Protein methylation at arginine comes of age. Cell. 2001;106:5-8. (Pubitemid 32709951)
3. Vallance P, Leone A, Calver A, Collier J, Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol. 1992;20:S60-2. (Pubitemid 23014109)
4. Böger RH, Bode-Böger SM, Thiele W, Junker W, Alexander K, Frölich JC. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation. 1997;95:2068-74. (Pubitemid 27184275)
5. Miyazaki H, Matsuoka H, Cooke JP, et al. Endogenous nitric oxide synthase inhibitor: A novel marker of atherosclerosis. Circulation. 1999;99:1141-6. (Pubitemid 29120084)
6. Goonasekera CD, Rees DD, Woolard P, Frend A, Shah V, Dillon MJ. Nitric oxide synthase inhibitors and hypertension in children and adolescents. J Hypertens. 1997;15:901-9. (Pubitemid 27344855)
7. Xiong Y, Fu YF, Fu SH, Zhou HH. Elevated levels of the serum endogenous inhibitor of nitric oxide synthase and metabolic control in rats with streptozotocin-induced diabetes. J Cardiovasc Pharmacol. 2003;42:191-6. (Pubitemid 36899670)
8. Valkonen VP, Päivä H, Salonen JT, et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet. 2001;358:2127-8. (Pubitemid 34094905)
9. Gorenflo M, Zheng C,Werle E, FiehnW, Ulmer HE. Plasma levels of asymmetrical dimethyl-L-arginine in patients with congenital heart disease and pulmonary hypertension. J Cardiovasc Pharmacol. 2001;37:489-92. (Pubitemid 32240431)
10. Stokes KY, Cooper D, Tailor A, Granger DN. Hypercholesterolemia promotes inflammation and microvascular dysfunction: Role of nitric oxide and superoxide. Free Radic Biol Med. 2002;33:1026-36.
11. Cosentino F, Eto M, De Paolis P, et al. High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human endothelial cells: Role of protein kinase C and reactive oxygen species. Circulation. 2003;107:1017-23. (Pubitemid 36258726)
12. Bagi Z, Cseko C, Tóth E, Koller A. Oxidative stress-induced dysregulation of arteriolar wall shear stress and blood pressure in hyperhomocysteinemia is prevented by chronic vitamin C treatment. Am J Physiol Heart Circ Physiol. 2003;285:H2277-83. (Pubitemid 37443042)
13. Feng Q, Lu X, Fortin AJ, et al. Elevation of an endogenous inhibitor of nitric oxide synthesis in experimental congestive heart failure. Cardiovasc Res. 1998;37:667-75. (Pubitemid 28231161)
14. Cable DG, Celotto AC, Evora PR, Schaff HV. Asymmetric dimethylarginine endogenous inhibition of nitric oxide synthase causes differential vasculature effects. Med Sci Monit. 2009;15:BR248-53.
15. Morris ST, McMurray JJ, Spiers A, Jardine AG. Impaired endothelial function in isolated human uremic resistance arteries. Kidney Int. 2001;60:1077-82. (Pubitemid 34205807)
16. Segarra G, Medina P, Ballester RM, et al. Effects of some guanidino compounds on human cerebral arteries. Stroke. 1999;30:2206-10.
17. Antoniades C, Shirodaria C, Leeson P, et al. Association of plasma asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling: Implications for endothelial function in human atherosclerosis. Eur Heart J. 2009;30:1142-50.
18. Sasaki K, Heeschen C, Aicher A, et al. Ex vivo pretreatment of bone marrow mononuclear cells with endothelial NO synthase enhancer AVE9488 enhances their functional activity for cell therapy. Proc Natl Acad Sci U S A. 2006;103:14537-41. (Pubitemid 44484785)
19. Wohlfart P, Xu H, Endlich A, et al. Antiatherosclerotic effects of small-molecular-weight compounds enhancing endothelial nitricoxide synthase (eNOS) expression and preventing eNOS uncoupling. J Pharmacol Exp Ther. 2008;325:370-9. (Pubitemid 351574784)
20. Riad A, Westermann D, Van Linthout S, et al. Enhancement of endothelial nitric oxide synthase production reverses vascular dysfunction and inflammation in the hindlimbs of a rat model of diabetes. Diabetologia. 2008;51:2325-32.
21. Fraccarollo D, Widder JD, Galuppo P, et al. Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction. Circulation. 2008;118:818-27.
22. Xue HM, He GW, Huang JH, Yang Q. New strategy of endothelial protection in cardiac surgery: Use of enhancer of endothelial nitric oxide synthase. World J Surg. 2010;34:1461-9.
23. Yang Q, Xue HM, Wong WT, et al. AVE3085, an enhancer of endothelial nitric oxide synthase, restores endothelial function and reduces blood pressure in spontaneously hypertensive rats. Br J Pharmacol. 2011;163:1078-85.
24. Yang Q, Ge ZD, Yang CQ, Huang Y, He GW. Bioassay of endothelium-derived hyperpolarizing factor with abolishment of nitric oxide and the role of gap junctions in the porcine coronary circulation. Drug Dev Res. 2003;58:99-110. (Pubitemid 36278502)
25. Yang Q, Hohimer RA, Giraud GD, et al. Effect of fetal anaemia on myocardial ischaemia-reperfusion injury and coronary vasoreactivity in adult sheep. Acta Physiol (Oxf). 2008;194:325-34.
26. Yang Q, Huang JH, Man YB, Yao XQ, He GW. Use of intermediate/ small conductance calcium-activated potassium-channel activator for endothelial protection. J Thorac Cardiovasc Surg. 2011;141:501-10.
27. Ge ZD, Zhang XH, Fung PC, He GW. Endothelium-dependent hyperpolarization and relaxation resistance to N(G)-nitro-Larginine and indomethacin in coronary circulation. Cardiovasc Res. 2000;46:547-56.
28. Yang Q, Zhang RZ, Yim AP, He GW. Release of nitric oxide and endothelium-derived hyperpolarizing factor (EDHF) in porcine coronary arteries exposed to hyperkalemia: Effect of nicorandil. Ann Thorac Surg. 2005;79:2065-71. (Pubitemid 40804188)
29. Huang JH, He GW, Xue HM, et al. TRPC3 channel contributes to nitric oxide release: Significance during normoxia and hypoxiareoxygenation. Cardiovasc Res. 2011;91:472-82.
30. Zhou W, Chai H, Courson A, et al. Ginkgolide A attenuates homocysteine-induced endothelial dysfunction in porcine coronary arteries. J Vasc Surg. 2006;44:853-62. (Pubitemid 44441774)
31. Roghair RD, Miller Jr FJ, Scholz TD, Lamb FS, Segar JL. Endothelial superoxide production is altered in sheep programmed by early gestation dexamethasone exposure. Neonatology. 2008;93:19-27. (Pubitemid 350277289)
32. Channon KM, Guzik TJ. Mechanisms of superoxide production in human blood vessels: Relationship to endothelial dysfunction, clinical and genetic risk factors. J Physiol Pharmacol. 2002;53:515-24. (Pubitemid 36014798)
33. Tarpey MM, White CR, Suarez E, Richardson G, Radi R, Freeman BA. Chemiluminescent detection of oxidants in vascular tissue. Lucigenin but not coelenterazine enhances superoxide formation. Circ Res. 1999;84:1203-11. (Pubitemid 29244782)
34. Laursen JB, Somers M, Kurz S, et al. Endothelial regulation of vasomotion in apoE-deficient mice: Implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation. 2001;103:1282-8. (Pubitemid 32221353)
35. Hink U, Oelze M, Kolb P, et al. Role for peroxynitrite in the inhibition of prostacyclin synthase in nitrate tolerance. J Am Coll Cardiol. 2003;42:1826-34. (Pubitemid 37433665)
36. Böger RH, Sydow K, Borlak J, et al. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: Involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res. 2000;87:99-105. (Pubitemid 30616904)
37. De Gennaro Colonna V, Bonomo S, Ferrario P, et al. Asymmetric dimethylarginine (ADMA) induces vascular endothelium impairment and aggravates post-ischemic ventricular dysfunction in rats. Eur J Pharmacol. 2007;557:178-85. (Pubitemid 46186290)
38. Fleming I, Fisslthaler B, Dimmeler S, Kemp BE, Busse R. Phosphorylation of Thr (495) regulates Ca(2+)/calmodulin-dependent endothelial nitric oxide synthase activity. Circ Res. 2001;88: E68-75.
39. Lin MI, Fulton D, Babbitt R, et al. Phosphorylation of threonine 497 in endothelial nitric-oxide synthase coordinates the coupling of L-arginine metabolism to efficient nitric oxide production. J Biol Chem. 2003;278:44719-26.
40. Michell BJ, Chen Z, Tiganis T, et al. Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein kinase. J Biol Chem. 2001;276:17625-8.
41. Greif DM, Kou R, Michel T. Site-specific dephosphorylation of endothelial nitric oxide synthase by protein phosphatase 2A: Evidence for crosstalk between phosphorylation sites. Biochemistry. 2002;41:15845-53. (Pubitemid 36062490)
42. Sud N, Wells SM, Sharma S, Wiseman DA, Wilham J, Black SM. Asymmetric dimethylarginine inhibits HSP90 activity in pulmonary arterial endothelial cells: Role of mitochondrial dysfunction. Am J Physiol Cell Physiol. 2008;294: C1407-18.
43. Skatchkov MP, Sperling D, Hink U, et al. Validation of lucigenin as a chemiluminescent probe to monitor vascular superoxide as well as basal vascular nitric oxide production. Biochem Biophys Res Commun. 1999;254:319-24. (Pubitemid 29290398)
44. Böger RH. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor. J Nutr. 2004;134:2842S-7. discussion 2853S.
45. Channon KM. Tetrahydrobiopterin: Regulator of endothelial nitric oxide synthase in vascular disease. Trends Cardiovasc Med. 2004;14:323-7. (Pubitemid 41110612)
46. Sharma S, Sun X, Kumar S, et al. Preserving mitochondrial function prevents the proteasomal degradation of GTP cyclohydrolase I. Free Radic Biol Med. 2012;53:216-29.
47. Sydow K, Hornig B, Arakawa N, et al. Endothelial dysfunction in patients with peripheral arterial disease and chronic hyperhomocysteinemia: Potential role of ADMA. Vasc Med. 2004;9:93-101. (Pubitemid 39406423)
48. Antoniades C, Demosthenous M, Tousoulis D, et al. Role of asymmetrical dimethylarginine in inflammation-induced endothelial dysfunction in human atherosclerosis. Hypertension. 2011;58:93-8.